Cancercare cancer survivors day

Well done Linda Greef for organising a excellent survivors summit at His Peoples Church in Goodwood.  It was well attended and everyone I spoke to was very impressed.

The summit was opened by Hanif Hamdulay from Cancercare.  (GVI have become Cancercare). They are a national network of oncology centres with 9 centres in the Western and Eastern Cape.

The MC for the morning was the charming Dr Michael Mol who trained as a medical doctor years
ago but has spent most of his working life in other areas including being a presenter on Top Billing.  The first speaker that he introduced was Conn Bertish, a cancer survivor and creator of Cancer Dojo.  What an incredible speaker.  What an incredible story.  He was diagnosed with a brain tumour and was teated with surgery and radiotherapy.  He has made an excellent recovery and is now a member of "the world's scariest club".  He has used his background in branding and advertising to set up Cancer Dojo.  The concept is fascinating and he encourages people to "take themselves out of helplessness".

The next speaker was the oncologist Dr Jill Harris, who Michael likened to the actress Sigourney Weaver.  She talked about the guidelines for follow up for cancer survivors.  The debate for many is about how many investigation should survivors have? Should they have regular expensive scans exposing them them to the risks of radiotherapy or should they be followed up symptomatically?  The point she made that really resonated with me was that seeing a well, longtime survivor for for a follow up is a privilege for all of us who work in the cancer field.

I spoke afterwards about some of the aspects of the the Na/utroceutical industry.  I will blog about my talk separately.

Rod Warner is a resilience consultant and author of the book "The Building Resilience Handbook".  His talk can be summed up with a phrase he used.  "Life is 10% what happens and 90% how you react to it".

DrAaron Motsoaledi (Minister of Health) was unable to join us and was ably represented by Prof Melvyn Freeman, the chief director of NCD from the Dept of Health.  He expanded the idea of a survivor being the individual with cancer to the notion of the family being survivors of the
experience.  However, the most poignant part of his speech, for me, was when he quoted from Mike Marqusee's book, The Price of Experience.

I was unable to stay for the parallel workshops which I heard were excellent.  To all of you who attended and helped organise the event: thank you


Isolates, Herbs and Formulations in Breast Cancer Care

Yesterday, I spent 3 hours at Cape Town's Mount Nelson Hotel listening to Dr Weber on the subject of isolates, herbs and formulations in breast cancer care.  I am not a homeopath and have never attended a lecture on the subject before.  I found it fascinating.

Dr Weber, the CEO of Panaxea, a company which "provides our practitioners with the most efficacious natural remedies available"  He is based in Australia and is a visiting professor at Tianjin
University.  His talk was based on the content of his book "Botanical Oncology:isolates" which was published in 2014.  He went through 220 slides and it would be an impossible task to even begin to summarise all the information presented. Nearly all the slides had a least one reference cited.

His talk was a mixture of traditional Chinese medicine, evidence based medicine and translational research. The different approaches were applied variously to different subtypes and stages of breast cancer.   I found it difficult to follow.  It is perhaps because I am not au fait with many of the concepts (eg phlegm which in traditional Chinese medicine apparently refers to interstitial fluid).  What bothered me was the lack of clinical outcome data.

When a drug is being developed, it has to go through at least 3 phases:
When a drug is being considered for use for cancer treatment, the oncologist wants to know whether or not the administration of the drug will lead to improved outcome (There has been a lot of criticism about the pharmaceutical companies.  Amongst other issues, they often do not publish the results when a drug is shown not to work and do not always take account of patient side effects).  Herbal products fall outside the current legislation omitting the need for outcome based studies, and controlled trials do not have to be conducted before they are marketed.

In a short three hours, an amazing number of products were discussed (I think, over 100) but survival data was given on only 90 patients: half of whom had received "herbs" or JLBSHJ formula.  All of the rest of the data was anecdotal.

Western medicine does not always get it right and there is an increasing demand from patients for Complementary and Alternative Medicine.  Dr Weber urged oncologists to engage in more dialogue with integrative oncologists.  I am encouraged by his commitment to "research and evidence based medicine" and am sure as the evidence for the usage of isolates, herbs and formulations in the management is produced, a more integrated approach will result.